A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects.
about
Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients.Natural Products from Microalgae with Potential against Alzheimer's Disease: Sulfolipids Are Potent Glutaminyl Cyclase Inhibitors.Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study
P2860
A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
A phase 1 study to evaluate th ...... nhibitor, in healthy subjects.
@en
A phase 1 study to evaluate th ...... nhibitor, in healthy subjects.
@nl
type
label
A phase 1 study to evaluate th ...... nhibitor, in healthy subjects.
@en
A phase 1 study to evaluate th ...... nhibitor, in healthy subjects.
@nl
prefLabel
A phase 1 study to evaluate th ...... nhibitor, in healthy subjects.
@en
A phase 1 study to evaluate th ...... nhibitor, in healthy subjects.
@nl
P2093
P2860
P1476
A phase 1 study to evaluate th ...... nhibitor, in healthy subjects.
@en
P2093
Antje Meyer
Frank Weber
Joseph Chiesa
Kerstin Kühn-Wache
Konrad Glund
Rolf Pokorny
Susanne Manhart
Torsten Hoffmann
Uli Bühring
P2860
P304
P356
10.1016/J.TRCI.2015.08.002
P577
2015-10-03T00:00:00Z